Efficacy and Safety Study of Drugs for Treatment of Visceral Leishmaniasis in Brazil

• Status: Terminated
• Trial end date: 2015-02-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is aimed to compare the efficacy and safety of medications currently used in Brazil for treatment of visceral leishmaniasis. The investigators will compare the effects of meglumine antimoniate, two formulations of amphotericin B: deoxycholate and liposomal, and a combination of meglumine plus the liposomal amphotericin B formulation. The study is designed to demonstrate the difference in efficacy measured as cure rate at six months after treatment and the safety profile based on the adverse event rate observed with each intervention.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Brasilia
• Collaborators: Conselho Nacional de Desenvolvimento Científico e Tecnológico; Drugs for Neglected Diseases; Ministry of Health, Brazil
• Treatments: Amphotericin B; Amphotericin B, deoxycholate drug combination; Deoxycholic Acid; Liposomal amphotericin B; Meglumine Antimoniate

Criteria

Inclusion Criteria:

• patients with visceral leishmaniasis characterized by fever plus hepatomegaly or splenomegaly with at least one positive result in the following laboratory tests:

• direct observation of leishmania amastigotes in bone marrow smear

• leishmania in vitro culture from bone marrow aspirates

• leishmania kDNA amplification by PCR in bone marrow or peripheral blood samples

• rK39 immunochromatographic rapid test performed on serum sample

Exclusion Criteria:

• pregnancy

• HIV infection

• chronic diseases such as diabetes mellitus,kidney, liver or cardiac diseases, schistosomiasis, malaria or tuberculosis

• immune disorders or use of drugs which interferes with the immune response

• treatment with drugs with increased risk for toxicity associated with the study drugs

• exposure to antileishmanial drugs during the past six months

• I.V. drug users

• episodes of visceral leishmaniasis relapse

• hypersensibility to the study drugs

• difficulties for accomplishing the follow-up schedule

• any of the following clinical signs of laboratory abnormalities: hepatic encephalopathy, generalized edema, toxemic individuals, severe malnutrition, jaundice, abnormal serum creatinine, bilirubin, INR > 2,0, platelet count < 20000/mm3